Johnson & Johnson and BARDA to Fund ~$1B in Research and Development of Novel COVID-19 Vaccines

Additionally, J&J to establish new vaccine manufacturing capabilities in the US and production capacity outside the US to begin production of the vaccine, will enable to supply ~1B doses of vaccine globally

Shots:

  • The collaboration follows the existing partnership b/w J&J and BARDA while the company expects to initiate the clinical studies of selected vaccine candidates by Sept’2020 with the anticipated first batch of COVID-19 vaccine to be available for EUA in early 2021
  • Under the new agreement, J&J and BARDA to invest ~1B in research, development & clinical testing of vaccines. J&J will utilize its validated vaccine platform and allocating resources to focus the efforts
  • Additionally, J&J to establish new vaccine manufacturing capabilities in the US and production capacity outside the US to begin production of the vaccine, will enable to supply ~1B doses of vaccine globally

Click here ­to­ read full press release/ article | Ref: J&J | Image: Fierce Pharma